company background image
PHXM logo

PHAXIAM Therapeutics NasdaqCM:PHXM Stock Report

Last Price

US$3.10

Market Cap

US$18.9m

7D

3.0%

1Y

-57.7%

Updated

12 Mar, 2024

Data

Company Financials +

PHAXIAM Therapeutics S.A.

NasdaqCM:PHXM Stock Report

Market Cap: US$18.9m

PHXM Stock Overview

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.

PHXM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PHAXIAM Therapeutics S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PHAXIAM Therapeutics
Historical stock prices
Current Share Price€3.10
52 Week High€13.00
52 Week Low€2.50
Beta1.8
1 Month Change-22.31%
3 Month Change-34.32%
1 Year Change-57.71%
3 Year Change-95.87%
5 Year Change-96.34%
Change since IPO-98.73%

Recent News & Updates

Recent updates

ERYTECH receives non-compliance letter from Nasdaq

Oct 13

Erytech Pharma reports 1H results

Sep 12

Erytech drops plans to pursue FDA approval for leukemia therapy

Aug 24

Our First Look At ERYTECH Pharma

Nov 16

ERYTECH Pharma S.A. 2021 Q1 - Results - Earnings Call Presentation

May 06

ERYTECH starts patient enrollment in pancreatic cancer study

Jan 14

ERYTECH secures €10M in non-dilutive financing

Nov 02

ERYTECH: Trials In Pancreatic Cancer

Oct 23

Shareholder Returns

PHXMUS BiotechsUS Market
7D3.0%0.9%0.4%
1Y-57.7%10.3%28.8%

Return vs Industry: PHXM underperformed the US Biotechs industry which returned 13.8% over the past year.

Return vs Market: PHXM underperformed the US Market which returned 30.9% over the past year.

Price Volatility

Is PHXM's price volatile compared to industry and market?
PHXM volatility
PHXM Average Weekly Movement16.1%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PHXM's share price has been volatile over the past 3 months.

Volatility Over Time: PHXM's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200445Thibaut Fayethttps://www.phaxiam.com

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.

PHAXIAM Therapeutics S.A. Fundamentals Summary

How do PHAXIAM Therapeutics's earnings and revenue compare to its market cap?
PHXM fundamental statistics
Market capUS$18.92m
Earnings (TTM)-US$13.06m
Revenue (TTM)US$6.23m

3.0x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHXM income statement (TTM)
Revenue€5.70m
Cost of Revenue€0
Gross Profit€5.70m
Other Expenses€17.66m
Earnings-€11.96m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Mar 20, 2024

Earnings per share (EPS)-1.97
Gross Margin100.00%
Net Profit Margin-209.79%
Debt/Equity Ratio41.3%

How did PHXM perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.